New research has confirmed the remarkable effectiveness of a six-monthly HIV prevention injection containing the antiretroviral drug lenacapavir. The latest study, PURPOSE 2, has shown that the injection is highly effective at preventing HIV infection among cisgender men, transgender men, transgender women, and non-binary individuals assigned male at birth. These findings echo results from PURPOSE 1, which demonstrated similar success…